ID   LNCaP C4-2
AC   CVCL_4782
SY   LNCaP-C4-2; LNCaP subline C4-2; C4-2; C42; Sp 2817
DR   ATCC; CRL-3314
DR   BTO; BTO:0005672
DR   Cosmic; 1330914
DR   Wikidata; Q54902814
RX   PubMed=8169003;
RX   PubMed=15162376;
WW   https://en.wikipedia.org/wiki/LNCaP
WW   https://web.archive.org/web/20150602153438/http://capcelllines.ca:80/details.asp?id=52
WW   http://www.thermofisher.com/ch/en/home/technical-resources/cell-lines/c/cell-lines-detail-464.html
CC   Characteristics: Exhibits androgen independent growth associated with skeletal metastasis, produces metastases when injected either subcutaneously or orthotopically in intact or castrated mice.
CC   Doubling time: 28.96 hours (https://www.synapse.org/#!Synapse:syn2347014).
CC   Sequence variation: Homozygous for AR p.Thr878Ala (c.2632A>G) (from parent cell line).
CC   Sequence variation: Heterozygous for MEN1 p.Tyr313Ter (c.939T>A) (from parent cell line).
CC   Sequence variation: Heterozygous for PIK3R1 p.Arg639Ter (c.1915C>T) (from parent cell line).
CC   Derived from metastatic site: Left supraclavicular lymph node.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens
HI   CVCL_4783 ! LNCaP C4
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 06-09-19; Version: 18
//
RX   PubMed=8169003; DOI=10.1002/ijc.2910570319;
RA   Wu H.-C., Hsieh J.-T., Gleave M.E., Brown N.M., Pathak S.,
RA   Chung L.W.K.;
RT   "Derivation of androgen-independent human LNCaP prostatic cancer cell
RT   sublines: role of bone stromal cells.";
RL   Int. J. Cancer 57:406-412(1994).
//
RX   PubMed=15162376; DOI=10.1002/pros.20031;
RA   Liu A.Y., Brubaker K.D., Goo Y.A., Quinn J.E., Kral S., Sorensen C.M.,
RA   Vessella R.L., Belldegrun A.S., Hood L.E.;
RT   "Lineage relationship between LNCaP and LNCaP-derived prostate cancer
RT   cell lines.";
RL   Prostate 60:98-108(2004).
//